22nd April 2022 | Pharma Updates
Piramal Foundation & Redwing Labs collaborated to explore automated drone technology for tuberculosis detection
Anamaya, a Piramal Foundation initiative, piloted automated drones for speedier conveyance of sputum samples for screening and diagnosis in Kalahandi district, Odisha.
EUA for Biological E's Corbevax for 5-11 years recommended by Govt panel
An expert panel of India’s central drug authority has recommended that Biological E’s COVID-19 vaccine Corbevax be given emergency use authorization for children aged five to eleven years.
Covid lockdown in China likely to suffocate Himachal's pharma hub
The supply of raw material to Himachal Pradesh’s pharmaceutical powerhouse in the Baddi-Barotiwala and Nalagarh industrial belt has been interrupted due to an indefinite shutdown in Shanghai, China’s commercial city, to control the spread of Covid-19.
Pfizer being criticized for refusing to give Paxlovid a required licence; been termed "betrayal of public trust"
Pfizer argued against the licencing, citing doubts about Paxlovid’s status as “the treatment of excellence” for COVID-19.
Sanofi begins work on a €400 million "factory of the future" in Singapore
The first of two Evolutive Vaccine Facilities (EVFs) that French pharma is building with a total investment of 900 million euros has begun construction.
Moderna plans to submit an EUA for the Covid-19 shot for extremely young kids
Moderna plans to submit an application to the USFDA by the end of the month for emergency use authorisation (EUA) of its Covid-19 vaccine in children aged six months to five years.
Sanofi claims that latest investigation of Rezurock can help with future studies
Sanofi has revealed data from two Rezurock trials that show a clear link between key organ responses and better patient-reported outcomes (PROs).
Revance BLA Resubmission for DaxibotulinumtoxinA approved by FDA
FDA has accepted Revance Therapeutics’ resubmission of its Biologics License Application for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.